Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Leiomyosarcoma of the prostate-an unexpected histopathological outcome.

Literature DB >> 27284101

Leiomyosarcoma of the prostate-an unexpected histopathological outcome.

Dinesh Harvey Raj¹, Prafulla Kumar Dash², Jayashree Mohanty¹, Pradosh Kumar Sarangi¹.

Abstract

Prostate leiomyosarcoma is an extremely rare and highly aggressive neoplasm that accounts for >0.1% of all primary prostate malignancies. We report a case of a patient, presenting with recurrent episodes of dysuria, who had been diagnosed and operated for benign prostatic hyperplasia 1 month earlier, and now presented with similar symptoms postoperatively. Trans-rectal biopsy of the prostate was carried out and histopathology revealed leiomyosarcoma of the prostate. 2016 BMJ Publishing Group Ltd.

Entities: Disease Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2016 PMID： 27284101 PMCID： PMC4904440 DOI： 10.1136/bcr-2016-215594

Source DB: PubMed Journal: BMJ Case Rep ISSN： 1757-790X

Keyword Cloud
References

16 in total

1. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.

Authors: L Serrone; M Zeuli; T Gamucci; M Nardi; F Cognetti
Journal: Cancer Chemother Pharmacol Date: 2001-03 Impact factor: 3.333

2. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

Authors: Revathi Suppiah; Laura Wood; Paul Elson; George T Budd
Journal: Invest New Drugs Date: 2006-11 Impact factor: 3.850

3. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors: M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal: J Urol Date: 1992-11 Impact factor: 7.450

Leiomyosarcoma of the prostate-an unexpected histopathological outcome.

1. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.

2. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

3. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

4. Leiomyosarcoma of the prostate. Report of 23 cases.

5. Adult urological sarcoma.

6. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience.

7. [Leiomyosarcoma of the prostate].

8. Leiomyosarcoma of prostate: a rare, aggressive tumor.

9. Prostatic leiomyosarcoma: the case for combined modality therapy.

10. Leiomyosarcoma of the prostate: case report and review of 54 previously published cases.